AMG 386 demonstrates antitumor activity in Phase 2 trial involving patients with recurrent ovarian cancer Amgen today announced that AMG 386, coupled with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian malignancy ed pills over the counter . AMG 386 is a first-in-class investigational peptibody that’s designed to block angiogenesis by inhibiting angiopoietin-1 and -2 . ‘The reality of ovarian tumor is that 80 % of women diagnosed in later phases will experience recurrence, often multiple times, and die from the disease eventually,’ said Beth Karlan, M.D., director of the Women’s Cancer Study Institute at Cedars-Sinai’s Samuel Oschin In depth Malignancy Institute and director of Cedars-Sinai Medical Center’s Division of Gynecologic Oncology.
The Company intends to use arises from the sale to lower debt.Â Â Â.. AMN sells home healthcare business to BAYADA AMN Healthcare Services, Inc. announced it has finished the sale of its home healthcare business to BAYADA Home Health Care, Inc. January 30 effective, 2012.65 million and retain working capital of around $4 million. Salka, the business’s chief executive officer. Due to this presentation, fourth quarter revenues from Continuing Functions are now expected to be between $219 million and $223 million, which is consistent with previous guidance excluding around $13 million of income associated with the home healthcare segment.